Seattle Genetics, Inc. (NASDAQ:SGEN) EVP Charles R. Romp sold 712 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $167.49, for a total transaction of $119,252.88. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Charles R. Romp also recently made the following trade(s):
- On Tuesday, May 12th, Charles R. Romp sold 6,942 shares of Seattle Genetics stock. The shares were sold at an average price of $166.00, for a total transaction of $1,152,372.00.
- On Friday, May 8th, Charles R. Romp sold 6,942 shares of Seattle Genetics stock. The stock was sold at an average price of $163.02, for a total transaction of $1,131,684.84.
Shares of NASDAQ:SGEN opened at $174.35 on Friday. The stock has a market capitalization of $30.38 billion, a PE ratio of -92.74 and a beta of 1.46. Seattle Genetics, Inc. has a 1 year low of $63.02 and a 1 year high of $182.97. The firm has a fifty day moving average price of $160.46 and a 200 day moving average price of $130.87.
Seattle Genetics (NASDAQ:SGEN) last announced its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.17). The company had revenue of $234.51 million during the quarter, compared to analyst estimates of $207.59 million. Seattle Genetics had a negative return on equity of 16.51% and a negative net margin of 32.81%. Seattle Genetics’s quarterly revenue was up 20.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.08) EPS. On average, equities analysts anticipate that Seattle Genetics, Inc. will post -2.79 earnings per share for the current year.
Several equities analysts have recently issued reports on SGEN shares. William Blair reiterated a “buy” rating on shares of Seattle Genetics in a research report on Thursday, July 2nd. Cfra upped their price target on Seattle Genetics from $122.00 to $129.00 and gave the company a “sell” rating in a research report on Friday, May 1st. Zacks Investment Research lowered Seattle Genetics from a “buy” rating to a “hold” rating and set a $132.00 price objective for the company. in a research report on Wednesday, April 15th. JMP Securities started coverage on Seattle Genetics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $185.00 target price on the stock. Finally, Stifel Nicolaus increased their price target on shares of Seattle Genetics from $120.00 to $127.00 and gave the stock a “hold” rating in a research report on Friday, May 1st. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Seattle Genetics currently has a consensus rating of “Buy” and an average target price of $147.42.
A number of institutional investors have recently made changes to their positions in the business. Synovus Financial Corp lifted its position in Seattle Genetics by 206.5% during the 1st quarter. Synovus Financial Corp now owns 331 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 223 shares during the last quarter. Ellevest Inc. grew its position in shares of Seattle Genetics by 753.3% in the second quarter. Ellevest Inc. now owns 256 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 226 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Seattle Genetics by 387.2% in the first quarter. Exchange Traded Concepts LLC now owns 458 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 364 shares during the period. Benjamin F. Edwards & Company Inc. lifted its position in shares of Seattle Genetics by 66.7% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 500 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 200 shares during the last quarter. Finally, CSat Investment Advisory L.P. lifted its position in shares of Seattle Genetics by 20.2% during the 1st quarter. CSat Investment Advisory L.P. now owns 624 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 105 shares during the last quarter. 94.33% of the stock is owned by hedge funds and other institutional investors.
Seattle Genetics Company Profile
Seattle Genetics, Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas.
See Also: What does a dividend yield signify to investors?
Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.